Looking For More Data: Lilly’s Arxxant Gets “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly is hopeful that data from an ongoing study will avoid the need for an additional trial.
You may also be interested in...
Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial
Company says Arxxant clinical data package presents a compelling case for the treatment of diabetic retinopathy.
Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial
Company says Arxxant clinical data package presents a compelling case for the treatment of diabetic retinopathy.
Arxxant’s Fate In Question After FDA Requests Additional Trial
Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.